Please use this identifier to cite or link to this item:
|Title:||Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats||Authors:||Ma, Z.
|Issue Date:||11-Apr-2005||Citation:||Ma, Z., Lim, T.M., Lim, L.-Y. (2005-04-11). Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. International Journal of Pharmaceutics 293 (1-2) : 271-280. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ijpharm.2004.12.025||Abstract:||The objective of the present study was to evaluate the effects of formulation parameters on the in vivo pharmacological activity of the chitosan-insulin nanoparticles. Chitosan-insulin nanoparticles were prepared by ionotropic gelation at pH 5.3 and 6.1 and denoted as F5.3np and F6.1np, respectively. F5.3np and F6.1np administered orally at insulin doses of 50 U/kg and/or 100 U/kg were effective at lowering the serum glucose level of streptozotocin-induced diabetic rats. The 100 U/kg-dose F5.3np sustained the serum glucose at pre-diabetic levels for at least 11 h. In comparison, F6.1np had a faster onset of action (2 h versus 10 h) but lower efficiency. The effectiveness of peroral F5.3np and F6.1np in lowering the serum glucose level of streptozotocin-induced diabetic rats was ascribed to the local effect of insulin in intestine. Confocal micrographs showed strong interaction between rat intestinal epithelium and chitosan nanoparticles 3 h post-oral administration. © 2005 Elsevier B.V. All rights reserved.||Source Title:||International Journal of Pharmaceutics||URI:||http://scholarbank.nus.edu.sg/handle/10635/101366||ISSN:||03785173||DOI:||10.1016/j.ijpharm.2004.12.025|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 23, 2020
WEB OF SCIENCETM
checked on Jan 15, 2020
checked on Jan 25, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.